RxDoctor Payments Data

Jason Cavanaugh, OD

Optometrist · Lisbon, CTNPI 1124183660

Payments from drug & device makers

$1,229in general payments, 2019–2025

Across 19 payments — averaging $64.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$481
  • Johnson & Johnson Vision Care, Inc.$196
  • Sun Pharmaceutical Industries Inc.$179
  • Tarsus Pharmaceuticals, Inc.$150
  • Amgen$105
  • Hoffmann-la Roche Limited$69
  • plus $49 from 2 others

What the payments were for

  • Food & beverage$1,229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,229 in reported general payments places this provider in the 55th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$77,244
Medicare patients
398
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost57$32,800
XiidraLifitegrast21$31,079
RestasisCyclosporine18$20,164
VyzultaLatanoprostene Bunod16$8,329
Restasis MultidoseCyclosporine11$7,065
Latanoprost339$5,978
Cyclosporine13$5,104
Timolol Maleate75$4,730
RocklatanNetarsudil Mesylat/Latanoprost11$3,569
Travoprost15$3,394
SimbrinzaBrinzolamide/Brimonidine Tart13$2,628
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,768
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat76$1,067
Prednisolone Acetate15$868
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose$30$60,02986 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$481$39,40837 claims
AlconSimbrinza$19$2,62813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 574 optometrist providers in Connecticut.

Other optometrist in Lisbon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →